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META-ANALYSIS: RISK OF TICS WITH PSYCHOSTIMULANT USE IN RANDOMIZED, 
PLACEBO-CONTROLLED TRIALS. 
Stephanie C. Cohen, Jilian M. Mulqueen, Eduardo Ferracioli-Oda, Zachary D. Stuckelman, Catherine G. 
Coughlin, James F. Leckman, and Michael H. Bloch. Child Study Center, Yale University School of 
Medicine, New Haven, CT. 
 
Clinical practice currently restricts the use of psychostimulant medications in children with 
tics or a family history of tics for fear that tics will develop or worsen as a side effect of treatment. 
Our goal was to conduct a meta-analysis to examine the risk of new onset or worsening of tics as an 
adverse event of psychostimulants in randomized, placebo-controlled trials. 
We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled 
trials examining the efficacy of psychostimulant medications in the treatment of children with 
attention-deficit/hyperactivity disorder (ADHD). We used a fixed effects meta-analysis with risk ratio 
of new onset or worsening tics in children treated with psychostimulants compared to placebo. We 
used stratified subgroup analysis and meta-regression to examine the effects of stimulant type, dose, 
duration of treatment, recorder of side effect data, trial design, and mean age of participants on the 
measured risk of tics. 
We identified 22 studies involving 2,385 children with ADHD for inclusion in our meta-
analysis. New onset tics or worsening of tic symptoms were commonly reported in the 
psychostimulant (event rate=5.7% (95% CI: 3.7% to 8.6%), I2 =72%, p<0.001) and placebo groups 
(event rate=6.5% (95% CI: 4.4% to 9.5%), I2 =64%, p<0.001). The risk of new onset or worsening of 
tics associated with psychostimulant treatment was similar to that observed with placebo (risk 
ratio=0.99 (95% CI: 0.78 to 1.27), z=-0.05, p=0.96). Type of psychostimulant, dose, duration of 
treatment, recorder of side effects, and participant age did not affect risk of new onset or worsening of 
tics.  Crossover studies were associated with a significantly greater measured risk of tics with 
psychostimulant use compared to parallel group trials. 
Meta-analysis of controlled trials does not support an association between new onset or 
worsening of tics and psychostimulant use.  Clinicians may want to consider re-challenging children 
who report new onset or worsening of tics with psychostimulant use, as these symptoms are much 
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Of note, the following introduction is based on a review I wrote with my research 
mentors of the clinical assessment of Tourette syndrome and tic disorders [1]. The 
remainder of the thesis is also based on our published work [2]. Please see Appendix A 
and Appendix B for a full copy of each article. 
Introduction 
Section 1. Background on Tics & Tourette Syndrome 
 
Tourette syndrome (TS) was first described by the French neurologist, Gilles de la 
Tourette, in 1885 as a “maladie des tics.” In his original case series describing the 
syndrome that now bears his name, Gilles de la Tourette wrote about many of the 
characteristics of the syndrome including: involuntary movements and sounds, markedly 
enhanced startle reactions, a tendency to repeat both vocalizations (echolalia) and 
movements (echopraxia), and uncontrollable verbal obscenities (coprolalia) [3]. Since 
then, our knowledge of TS has progressed significantly, including advances in our 
understanding of tics, their surrounding sensory phenomena, and the central role that 
other co-occurring diseases, such as Attention Deficit Hyperactivity Disorder (ADHD) 
and Obsessive-Compulsive Disorder (OCD), have on the overall clinical course of the 
disorder. This introduction will focus on our current understanding of the diagnosis, 
clinical characterization and assessment of tics as well as their clinical course. Because of 
the large overlap between TS and ADHD, a background on use of psychostimulants and 
tics will be provided as well.  
Definition of tics: 
 
Tics appear as sudden, rapid, purposeless motor movements or sounds that 
involve discrete muscle groups. They are also stereotyped in that they will occur in a 




disorders or psychiatric conditions (e.g. Sterotypies, Chorea, or Dyskinesia), patients with 
tics report the ability to suppress them, even if only for a short duration. However, they 
report that suppression often causes discomfort. Almost any movement, sound, or 
combination therein that the body can make can become a tic. Although some tics are 
more mild (i.e. eye blinking), others can be more severe to the point of causing pain to 
the patient (i.e. head or neck jerk). Apart from the physical consequences incurred by 
them, tics and their associated neuropsychiatric symptoms can diminish patients' quality 
of life, social and academic function, and lifetime achievements. They can also be very 
troubling and disruptive to the patients' family, and many times the entire family needs 
care and counseling [4]. Oftentimes, the tics themselves have less adverse effects than the 
co-occurring disorders. For instance, a 2011 study measuring quality of life (QoL) in fifty 
youth with TS found that symptoms of depression, OCD, and ADHD appeared to have a 
widespread negative impact on QoL; however, increased tic severity and poor QoL were 
not associated [5]. 
Tourette Syndrome and other tic disorders: 
 
The prevalence of TS varies based on study design and location. An international 
prevalence of 0.6% – 1% has been reported for mainstream schoolchildren, with the 
disorder being 3–4 times more common in males than in females [6]. Data from the 2007 
National Survey of Children's Health (NSCH) showed an estimated prevalence of 0.3% 
among U.S. children aged 6–17 years [7]. This number may represent an underestimate 
of TS prevalence since data were gathered from a parent- reported survey, and detection 
might be imperfect for children with fluctuating levels of symptoms or limited access to 




worldwide due to either genetic or environmental differences. For example, TS has been 
reported to be less common in African-American people and has been reported only very 
rarely in sub-Saharan black African people [8]. Regardless, the phenomenology of TS is 
similar in all cultures in which it has been reported [8]. 
TS is defined by the pediatric onset of both motor and vocal tics, lasting for at 
least one year. Although TS is the most notorious cause of chronic tics, there are types of 
tic disorders that are more common in children. Based on the Diagnostic and Statistical 
Manual–5 (DSM-5) of the American Psychiatric Association, other tic disorders include: 
Persistent (Chronic) Motor or Vocal Tic disorder (CMT), which is defined as 
having motor or vocal tics (but not both) for more than one year; and Provisional Tic 
Disorder, which is characterized by single or multiple motor and/or vocal tics for a 
duration of less than one year [9]. Transient tics affect 15–25% of school-aged children 
with the majority experiencing resolution of tics within several months [8, 10-12]. Other 
Specified Tic Disorder or Other Unspecified Tic Disorder are the diagnostic terms used 
for tic disorders that begin after age 18, are secondary to other factors such as substance 
use (e.g. cocaine), toxins (e.g. carbon monoxide poisoning), or head trauma (e.g. physical 
trauma, stroke, or encephalitis), or do not fit in the above-mentioned categories [9]. 
Table 1. Tic Disorders according to DSM-5 




and one or 
more vocal tics 
Tics may wax and wane in frequency but 
have persisted for >1 year since first tic 
onset 
<18 years of age 
Persistent 
(Chronic) Motor 





vocal tics (but 
not both) 
Tics may wax and wane in frequency but 
have persisted for >1 year since first tic 
onset 










Tics have been present for <1 year since 
first tic onset 
<18 years of age 
Other Specified 
Tic Disorder  
Motor or vocal Tic disorder symptoms present, which 
cause clinically significant distress or 
impairment, but do not meet full criteria 
for a tic disorder for a specific reason 
(e.g., “with onset after age 18 years”) 
Often used for 
individuals that 
have onset at >18 
years of age 
Unspecified Tic 
Disorder 
Motor or vocal Tic disorder symptoms present, which 
cause clinically significant distress or 
impairment, but do not meet full criteria 
for a tic disorder for a reason that is not 
specified by the clinician, often because 
there is insufficient information to do so 
N/A 
 
Tics also exhibit several characteristics that distinguish them from other common 
childhood movement disorder such as stereotypies, choreas and dystonias. The 
distinguishing characteristics of tics include (1) they wax-and-wane in severity, (2) the 
character of the movements changes over time, (3) they are temporarily suppressible and 
(4) they are typically associated with sensory phenomena. Table 2 contrasts TS with other 
common movement and childhood psychiatric disorders confused with TS. 
Table 2. Differential Diagnosis of Tic Disorders 







 Abrupt, stereotyped 
coordinated movements or 
vocalizations that often mimic 
aspects of regular behavior 
 Wax and Wane 
 The character of the movements 
changes over time 
 Temporarily suppressible 
 Premonitory urges are common 
 Exacerbated by stress and relieved by 
distraction 
 Tourette’s Disorder 
 Persistent (Chronic) Motor or Vocal 
Tic Disorder 




 Repetitive, purposeless, and 
apparently voluntary movements 
 Autism 
 Pervasive Developmental Disorder 
 Mental Retardation 









 Simple, random, irregular, and non-
stereotyped movements 
 Has no premonitory component and 
increases when the person is 
distracted 
 Often flows from one body part to 
another 
 Normal in children less than 8  
months of age 
 Cerebral Palsy 
 Sydenham's Chorea 
 Hereditary choreas 
 Kernicteris 
 Lesch-Nyhan syndrome 





 Slow, protracted twisting movements 
interspersed with prolonged states of 
muscular tension 
 Drug-induced 
 Idiopathic torsion dystonia 
 Anoxia or stroke 
 Wilson's disease 
 Huntington's Disease 




 Slow, irregular, writhing movements. 
Usually involving fingers and toes 
but occasionally the neck 
 A “slow chorea” 





 Brief, simple, shock-like muscle 
contractions that may affect 
individualized muscles or muscle 
groups. 
 Physiologic: hiccups, anxiety, or 
exercise- induced 
 Pathologic: Juvenile Myoclonic 
Epilepsy, Metabolic 
encephalopathies, Creutzfeldt-Jakob 




 Involuntary movement associated 
with a specific voluntary act, i.e. 




Characterization of Tics: 
 
Tics are characterized by their anatomical location, number, frequency, and 
duration. They are also further described by their forcefulness or intensity and by their 
complexity (ranging from simple to complex). The most widely-used rating scale of tic 
severity is the Yale Global Tic Severity Scale (YGTSS), which includes separate scores 
from 0–5 for number, frequency, intensity, complexity, and interference (the degree to 
which planned actions or speech are interrupted by tics) of both motor and phonic tics 
[13]. This tool has allowed for the standardization of tic severity across different studies 




Additionally, because the clinical characteristics of TS make it hard for clinicians 
to diagnose and assess the severity of the condition, the Tourette Syndrome Diagnostic 
Confidence Index (DCI) was created through a collaborative effort of an expert group of 
clinicians. Based on the range and complexity of tics, their changeable nature, the 
temporal features of tic expression, and associated subjective and cognitive experiences, 
the DCI assigns a score from 0 to 100, which reflects the likelihood of having or ever 
having had TS [14]. 
Other rating scales include the Shapiro Tourette Syndrome Severity Scale, 
Tourette's Syndrome-Clinical Global Impression Scale, and the Hopkins Motor and 
Vocal Tic Scale [15]. Standardized video recordings can also be used to count tics [16]. 
See Table 3 for a detailed comparison of various rating scales. For a detailed discussion 
on these rating scales, please refer to a recently published review [17]. 
Table 3. Tic Rating Scales 
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Note: ADHD = Attention-Deficit Hyperactivity Disorder; OCD = Obsessive Compulsive 
Disorder; MDD = Major Depressive Disorder; IED = Intermittent Explosive Disorder 
 
Natural History of Tourette Syndrome: 
 
The natural history of TS has been established based on clinical observations. 
There is a clear progression of the disorder from the onset of symptoms to, in most cases, 
full or partial regression of symptoms. Tics usually begin around 6–8 years of age, and 
90–95% of TS cases have an onset of tics between the ages of 4–13 [26]. Simple motor 
tics involving the eyes or face are usually the first to appear in a child with TS. They are 
called simple because they involve a single contraction, such as a shoulder shrug or neck 
stretch. Motor tics will typically progress in a rostral-caudal fashion and over time they 
have a tendency to become more complex, involving contractions of groups of muscles in 
a stereotyped, repetitive way [26]. As such, complex motor tics are often difficult to 
distinguish from compulsive behaviors. 
Phonic tics usually appear after the onset of motor tics and can also progress from 
simple vocalizations to more complex ones. Although a distinction is made between 
phonic and motor tics, it is a tenuous one as the sounds produced are a result of 
contractions of laryngeal, respiratory, oral, or nasal musculature [27]. Simple phonic tics 




squeaking, or sniffing, while complex phonic tics can include uttering different words or 
phrases. In the same category, echolalia (repeating the words or sounds of others), 
palilalia (repeating oneself), and coprolalia (saying obscene words or phrases) are types 
of complex phonic tics. Table 4 describes and gives examples of simple and complex 
motor and phonic tics. 
Table 4. Types of Tics 
 Motor Phonic 
Simple Sudden, brief, short (usually <1 second), one group 
of muscles (e.g. eye blinking, facial grimacing, 
head jerk, shoulder shrug) 
Fast, meaningless sounds/noises (e.g. 
sniffing, throat clearing, grunting, or 
high-pitched squeaks) 
Complex Sudden, appear purposive, stereotyped, longer 
duration, coordinated movements 
Syllables, words, or phrases; odd 
patterns of speech with changes in 
rate, volume, or rhythm 
Echopraxia: copying gestures of others Echolalia: repeating words or phrases 
of others 
Palipraxia: repeating one's own gestures Palilalia: repeating one's own words or 
phrases 
Copropraxia: lewd and obscene gestures with hands 
or tongue 
Coprolalia: socially inappropriate 
syllables, words, or phrases 
expressed in a loud, explosive 
manner 
Dystonic: sustained, gyrating, bending, or twisting 
movement or posture (e.g. blepharospasm, 
oculogyric movements, mouth opening, shoulder 
rotation) 
 
Tonic: sustained, isometric contraction (e.g. 
abdominal or limb tensing) 
 
Self-injurious Behavior: tics that involve injuring 




Tics tend to wax and wane in severity and frequency. Both motor and phonic tics 
arise in bouts over the course of the day, and they change in severity over weeks and 
months. Thus, the amount and length of tic-free intervals throughout the day determines 
to some extent the severity of the symptom. The tic itself can be more or less forceful, 




By contrast, there are no factors known to affect the long-term course of tics. 
However, the vast majority of children with tics improve. The severity of tics usually 
peaks at about 10–12 years of age, and in one half to two thirds of cases, symptoms will 
drastically reduce during adolescence [29] (Fig. 1). In the rare cases in which tic severity 
persists into adulthood, tic symptoms are most severe, characterized by self-injurious 
motor tics or coprolalic utterances [28]. 
 
 
Fig. 1. Average tic severity from age 2 to 18 years. Adapted with permission from [26]. 
 
In fact, in a recent study by Freeman et al., the overall prevalence of 
coprophenomena was 19.3% in an international cross-sectional sample of 597 patients. 
Only 15 of 220 individuals who had mildly-rated tics had coprolalia; whereas 42.6% of 
the 108 patients with severe tics had coprolalia. The mean age of onset of coprolalia and 




tics. This delayed onset and greater percentage of coprolalia seen in patients with severe 
tics is not surprising, as coprophenomena reflects more complex tics and comorbidity 
patterns [30]. 
Other studies have also associated the presence of certain types of tics with 
clinical course. A recent study by Martino et al. looked at the prevalence of eye tics in TS 
patients. They found that of 212 patients, 201 or 94.8%, reported ever having eye tics in 
their lifetime. They also discovered that overall tic severity positively correlated to 
lifetime history of eye and/or eyelid/eyebrow movement tics. Furthermore, they found 
that regardless of the type of tic at onset, patients with a lifetime history of eye movement 
tics had an earlier onset of TS than those who had never had eye movement tics. These 
findings suggest the possibility for a difference in the natural history of patients with and 
without ocular tics [31]. 
Few studies have examined predictors of long-term outcome on 
neuropsychological assessment and neuroimaging. One cohort that examined 43 children 
with TS followed to young adulthood demonstrated that smaller childhood caudate 
volume and poor Purdue Pegboard performance were associated with increased tic 
severity in early adulthood [32, 33]. Purdue pegboard performance is a test of fine-motor 
skill, and poor performance may be a sign of deficits in complex, visually guided or 
coordinated movement that is likely mediated by circuits involving the basal ganglia. 
Reduced caudate volume has been previously demonstrated to be a morphological trait of 
TS on structural MRI [34, 35]. 





The outward manifestation of TS represents only a part of the symptomatology 
experienced by most of our patients. In 1980, Joseph Bliss, articulately described his 
careful observations from 35 years of self-study of the feelings and subjective events 
surrounding his own tics. Much of what he described became the basis for future research 
surrounding the sensory phenomena associated with tics. The term, “sensory 
phenomena,” is now used as an all- encompassing term to describe such subjective 
experiences as premonitory urges, “just- right” perceptions, or somatic hypersensitivity in 
an effort to unify terminology across the literature [36]. 
Premonitory Urges: 
 
Premonitory urges (PU) are uncomfortable sensory phenomena that typically 
precede and are subjectively experienced as being the initiators of tics. Premonitory 
urges, formerly deemed, “sensory tics,” can be experienced by individuals with tics and 
are likened to the need to sneeze or itch or an inner feeling of restlessness, pressure or 
mounting tension [37]. In a questionnaire administered to 135 patients with tic disorders, 
it was shown that the anatomical regions with the greatest density of urges were the 
palms, shoulders, midline abdomen, and throat [38]. Thus, premonitory urges are focal in 
character and limited to specific anatomical locations. They can also vary in frequency, 
intensity, and location. The performance of the tic itself is usually associated with a 
momentary feeling of relief from this uncomfortable urge. 
The premonitory urge has been studied in comparison with other normal 
physiological urges, such as the urge to urinate, cough, blink or sleep. An urge is one 
mode of processing internal or external sensory input into motor output. However, an 




alone outside of our awareness, and the action would thus be perceived as involuntary 
[39]. 
Similarly, Bliss writes when describing the process of a tic that: “the inception 
and emergence of a single action and its passage into the overt phase is so faint, subtle, 
surreptitious, and lightening fast that rarely is it known to the subject that it exists at all” 
[40]. 
If the action is delayed, an urge develops. This feeling of a need to act is different 
from the sensation of the sensory input itself. Typically, the discomfort associated with 
the premonitory urge builds up until the tic is performed. Some patients state that they 
will voluntarily make tics in response to the urge in order to relieve themselves of the 
mounting discomfort. 
In 1994, Kane, then a graduate student with TS, wrote in reference to premonitory 
urges, “these sensations are not mere precursors to tics; […] more than providing a signal 
of imminence, the pre-tic sensation acts as the aversive stimulus toward which tics are 
directed” [41]. 
Patients with TS have the ability to suppress tics temporarily but only at the 
expense of mounting discomfort like suppressing a sneeze, itch, or the urge to urinate. In 
fact, with prolonged suppression, the urge to tic can become so great that the action 
occurs beyond the patients' control. In this way, tics have been called “un-voluntary,” 
since they are neither voluntary nor involuntary. In contrast to normal urges, the urge to 
tic is different in that the sensory input that generates the urge to tic is unknown, tics are 
not key to survival – in fact, they are both nonessential and nonproductive –, and the 




individuals with tics sometimes report the need to perform tics until they get the feeling 
associated with it being “just right.” 
It remains possible that abnormal perception or filtering of these sensory 
phenomena may be central to the pathogenesis of TS (see “Sensorimotor gating” below). 
Several individuals with tics have suggested that these premonitory urges may be as 
characteristic of TS and as disruptive and distracting as the tics themselves. Some 
individuals perceive premonitory urges and other sensory phenomena as being the “core” 
of TS [42]. 
Furthermore, patients have reported an awareness of the premonitory urge helps 
them suppress imminent tics because they are fore-warned of their arrival and can take 
measures to suppress them. Along these lines, certain types of behavioral therapies have 
been developed in order to take advantage of this awareness. Premonitory urges are 
utilized in cognitive-behavioral interventions that include empirically supported 
behavioral therapy [43] and exposure and response prevention [44]. 
Awareness of premonitory urges typically increases as children with TS become 
older [45]. Individuals with TS have reported that they first became aware of their 
premonitory urges on average 3.1 years after the onset of tic symptoms [38]. The delayed 
onset of awareness of urges most likely represents the normal development self-
awareness and the fact that younger children are less able to recognize and describe 
bodily urges. Premonitory urges are experienced by most adolescents and adults with TS. 
Eighty-two to ninety-two percent of patients will report experiencing premonitory urges 




Whether a tic is voluntary or involuntary has been the topic of much study. Some 
have said, the tic is a voluntary action performed in an attempt to relieve an involuntary 
urge [40]. Furthermore, in a 2003 study, 68% of 50 TS subjects described a motor tic as a 
voluntary motor response to an involuntary sensation, as opposed to a completely 
involuntary movement [47]. Also, in a study involving 135 individuals with TS, 92% of 
individuals indicated that their tics were either fully or partially a voluntary response to 
their premonitory urges. Also, in the same study, 84% of these subjects reported that their 
tics were associated with a momentary feeling of relief [38]. 
The Premonitory Urge for Tics Scale (PUTS) is a rating scale designed to 
measure the strength of these premonitory urges in tic disorders. Although premonitory 
urges have been difficult to recognize and consistently report for youth under the age of 
10, the scale was found to have excellent psychometric properties for children above the 
age of 10 years, with PUTS scores correlating with tic severity as measured by the 
YGTSS [48]. 
Table 5. Sensory Phenomena Rating Scales 
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Sensorimotor gating describes the neurological processes of filtering out 
redundant or unnecessary sensory stimuli from all possible environmental stimuli. 
Individuals with TS (and schizophrenia) have consistently demonstrated deficits in 
sensorimotor gating as compared to healthy controls. Prepulse inhibition (PPI) of startle 




gating. Prepulse inhibition of startle is defined as the inhibitory effect of a low-intensity 
stimulus or “prepulse,” on the startle response to the subsequent same, but high-intensity 
stimulus [52]. The prepulse is believed to activate brain mechanisms which suppress or 
“gate” the processing of that stimulus for a brief window of time. Impaired PPI has been 
shown in patients with TS, and recently lesions in the dorsomedial striatum have been 
implicated in their diminished capacity for PPI [52]. Swerdlow has demonstrated PPI is 
regulated by both norepinephrine and dopamine substrates, and clonidine can repair PPI 
disrupted by cirazoline [53]. 
As hypothesized by these sensorimotor gating deficits observed in patients with 
TS, many individuals describe hypersensitivity as being an important phenomenon 
intertwined with other aspects of the disorder. A salient example of this phenomenon is 
the extreme sensitivity to tags in new clothing experienced by some children with TS. 
These experiences are described well in the following quotes:  
“Because of the state of sensitization (combined with memory recall and attention 
targeting), this site is the most difficult to extinguish. Paradoxically, for the same 
reasons it is the one most likely to be extinguished first in any period of 
remission” [40]. 
 
“All these sensory actions can dart from one to another with great speed and 
varying intensities, at times escalating to a fever pitch of intensity and at other 
times fading quickly away, to recur some other time. Often the effort to control 
these wild sensations seems to be more than the human spirit can bear; there are 
really only two choices: let it all hang out or keep fighting. However great the 
confusion and diversity of sensory-related actions and sensations, only one of 
these is active at any given moment. All others, residual and secondary, stand in 
the wings, with their entrances and exits following so quickly on after the other 
that it is very hard at times to be aware of their single movements” [40]. 
 
“Perhaps the best description for the sensory state of TS is a somatic hyper-
attention: It is not as itch-like as it is an enduring somatosensory bombardment. I 
experience the TS state as one of keen bodily awareness, or a continual 
consciousness of muscle, joint, and skin sensations. For example, when sitting in 




body, nor can I ignore the deeper somatic sensations of what my back and legs 
feel like” [41]. 
 
“How does a new tic get started? The activation of TS sites is dependent on a 
combination of (1) attention direction and (2) various precipitants such as stress, 
tactile and kinesthetic perceptions, previous sensitization of a site, inadvertent 
pressure points anywhere on the body, memory recall of the earlier sites, and 
phantom fixations. […] The subject's attention, for any of a multitude of chance 
reasons, can fall on any potential site. Over seconds, minutes, or hours, the 
attention shifts to numberless places via sounds, sights, touch, pressure, 
discomfort, pain, temperature, or thoughts. In the normal person, these attention-
exciting events can go relatively unnoticed. In the person with TS, anyone can set 
off a TS action even though that person may be completely unaware of the 
stimulating factor” [40]. 
 
In 2011, Belluscio et al. studied in detail the experience of sensitivity to external 
stimuli in a case-control study of 19 TS patients and 19 age-matched healthy volunteers. 
An in-depth interview and questionnaire revealed that 80% of TS patients reported 
heightened sensitivity to external stimuli, with examples among all sensory modalities, 
but with statistically significant heightened sensitivity to 4 of 5 sensory modalities 
(sound, light, smell, and touch) as compared to the healthy volunteers [54]. They found 
bothersome stimuli were characterized as “faint, repetitive or constant, and nonsalient, 
whereas intense stimuli were well tolerated” [54]. Examples of such bothersome stimuli 
include: rough fabrics, the constant pressure exerted by a shirt collar or a waistband, the 
pressure of a chair or another person's arm. Patients also described a preference for strong 
tactile stimuli such as having their skin scratched or receiving a massage. Furthermore, 
these investigators did not observe in TS patients any greater ability to detect different 
intensities of olfactory and tactile stimuli as compared to healthy volunteers. This led 
them to suggest that the perceived sensitivities were the result of altered or impaired 




Several rating scales have been designed to measure this hypersensitivity 
experienced by those with TS. The University of Sao Paulo Sensory Phenomena Scale 
(USP-SPS) was designed in 2005 in order to assess the severity and frequency of sensory 
phenomena that precede, accompany, or follow tics and other repetitive behaviors, such 
as compulsions or rituals [55]. Furthermore, in 2009 it was validated against other 
established scales, such as the Yale-Brown Obsessive-Compulsive Scale, Dimensional 
Yale-Brown Obsessive-Compulsive Scale, Yale Global Tic Severity Scale, Beck Anxiety 
Inventory, and Beck Depression Inventory, as a reliable instrument for measuring the 
presence and severity of sensory phenomena in individuals with OCD [49]. 
In addition to PPI as an experimental measure of sensorimotor gating, the 
Structured Interview for Assessing Perceptual Anomalies (SIAPA) and the Sensory 
Gating Inventory (SGI) are rating scales that were developed in order to quantify 
sensorimotor gating impairment seen in TS and schizophrenic patients. SIAPA was 
developed in 1999 as a way to measure perceptual anomalies, such as flooding or 
inundation of sensory stimuli in individuals with schizophrenia. The interview employs 
Likert ratings of perceived hypersensitivity, inundation, and selective attention to external 
sensory stimuli [51]. 
Furthermore, Hetrick et al. created the self-report rating scale, Sensory Gating 
Inventory (SGI) in an effort to expand upon the SIAPA scale by employing an empirical, 
factor analytic procedure to assess and systematically identify the phenomenology and 
major dimensions of sensory gating. The self-report rating scale also employs Likert 
ratings of subjective experiences, such as: perceptions of heightened stimulus sensitivity, 




exacerbation of sensory gating-like anomalies by fatigue and stress. The SGI scale 
demonstrated strong reliability and validity [50]. 
Exacerbating/Alleviating Factors: 
 
Tic symptoms vary in frequency and intensity, and in addition to potential 
neurological variation, it has been shown that certain environmental or contextual factors 
will either exacerbate or alleviate tic symptoms in individuals with TS. 
The results of 6 different descriptive studies looking at the effects of different 
antecedent variables on tic severity show stress and anxiety appear to be the most 
common factors associated with an increase in TS symptoms, while fatigue and boredom 
also rank high on the list [56]. On the other hand, relaxation, concentration, and physical 
exercise were antecedent factors shown to contribute to tic attenuation [56]. These studies 
are limited by the fact that they describe aggregate data, thus removing individual 
experiences from the descriptions, and they are subject to bias because data were 
collected by self report and parental observation. 
Experimental designs studying the impact of various antecedent factors on tic 
expression show tic expression occurs more frequently in cases of direct, overt 
observation, during easy reading assignments, and when the tics themselves are spoken 
about. For instance, more tics were observed when children were overtly, as opposed to 
covertly, observed by a video camera; and the presence of another person in the room did 
not affect overall tic counts [57]. Also, direct observation revealed tics are aggravated by 
easy reading assignments, reading in a quiet classroom, and by the period between 
assignments [58]. Conversely, it has been shown that periods of focused attention to tasks 




revealed tic-related conversations increase the frequency of phonic tics (not motor tics) as 
compared to conversations that do not have to do with tics [60]. Additionally, instructions 
to suppress tics have been shown to modestly reduce tic frequency, at least for 30 
minutes, with adults demonstrating suppression more frequently. In this same study of 7 
adults and children, tic suppression did not lead to the rebound effect of increased tic 
frequency after the period of suppression, but the impact of suppression instructions on 
strength of premonitory urges ratings remains unclear [61]. 
Furthermore, taken together, multiple studies have suggested stress, anxiety, 
frustration, and tension are emotional variables often associated with an increase in tics 
[56]. However, it remains unclear as to why certain emotions exacerbate tics and what 
their effect is on premonitory urges. With regard to consequent factors that affect tic 
expression, it has been shown reinforcing tic-free periods acts to reduce tic frequency, 
while paying attention to the tics themselves or publicly commenting on tics increases 
these symptoms [56]. 
Table 6. Exacerbating and Alleviating Factors 
Tic Attenuation Tic Exacerbation 
Relaxation Stress, anxiety, worry, frustration 
Physical exercise, sports Fatigue, tiredness 
Concentration, study activity Returning to school 
Habitual, automatic actions Boredom, waiting 
Reading for pleasure Emotional trauma 
Leisure activity Holidays, birthdays 
Talking to friends Working under pressure 
Doctor visits Overstimulation, multitasking 
Verbal instructions to suppress tics and 
rewarding/reinforcing tic-free periods 
Tic-related conversation 
Interaction with familiar people Being alone 
Socialization (30%), social gatherings (25%) Social gatherings (42%), socialization (50%) 
(presence of others/overt observation) 
 Transportation 






One of the characteristics of tic symptoms is that they are suppressible, even if 
only for a short while. However, as stated earlier, the act of suppression can lead to the 
build-up of uncomfortable premonitory urges. In one study, 3 of 4 children who 
demonstrated reliable suppression showed a pattern of higher subjective urge ratings 
during suppression as compared to baseline [62]. 
Although tics can be suppressed, to do so requires more attention and energy from 
the individual. For instance, in a study involving 9 children with TS, ages 9–15, accuracy 
and performance on a distraction task was reduced while children were simultaneously 
told to suppress tics as compared to free-to-tic conditions [63]. However, no significant 
difference was demonstrated between tic frequencies during periods of reinforced 
suppression and reinforced suppression plus a distraction task. This study demonstrates 
accuracy on an attention-demanding task may be impacted if a child is simultaneously 
trying to suppress their tics: a finding that has strong implications on school performance 
for children with TS. This finding suggests school performance of children with TS may 
be impacted not only by tics but by the attention devoted to suppressing tics and 
highlights the importance of a supportive environment where negative feedback from 
their peers and teachers in response to tics is minimized. 
Stress has been shown to be one of the major factors associated with tic 
exacerbation. In a study involving 10 youth with TS, ages 9–17, it was demonstrated that 
stress impacts children's ability to suppress tics but not necessarily their baseline tic 
frequency. Tic frequency was greater during periods of reinforced suppression plus a 




different between free-to-tic baseline levels and periods when applied stress was added to 
this condition [64]. 
Additionally, it has been shown that tic suppression rewarded for tic-free intervals 
is more successful at reducing tic frequency than is just being told to suppress tics. For 
instance, in a study design in which tokens were delivered both contingently on the 
absence of tics and non-contingently, tic frequency was lower in 3 of 4 children during 
the former condition. The success of reinforced tic suppression could be one of the 
reasons children are seen to tic more at home than in the classroom because tic absence is 
reinforced in the classroom by the avoidance of teasing from peers [65]. Alternatively, it 
is possible tic frequency is greater at home than in the classroom because children 
become more tired by the end of the day when they return home from school. 
Finally, one concern with the use of reinforced tic suppression as a model for 
therapy is the potential for a tic rebound effect, which describes an increase in frequency 
of tics after suppression. However, studies have not supported such concerns. Although 
tic frequencies have been shown to increase post-suppression as compared to during 
suppression, they do not increase above pre-suppression levels [66]. Another study 
demonstrated similar findings after repeated 2-hour sessions of Exposure and Response 
Prevention (ER), a behavioral treatment program, consisting of habituation to 
premonitory sensory experiences during prolonged tic suppression. The study 
demonstrated successful ER as this treatment resulted in a reduction of tics by 91% as 
compared to baseline. However, comparison of 15 minute pre- and post-suppression 




one study noted the absence of the rebound effect in the 5 minutes following reinforced 
tic suppression during periods of up to 40 consecutive minutes [68]. 
Comorbidities: 
 
The description of behavioral and emotional disturbances in patients with TS has 
occurred since 1899, around the time the disorder was first described by Georges Gilles 
de la Tourette himself [69]. In fact, comorbid neuropsychiatric disorders, the majority 
being ADHD and OCD, have been shown to occur in up to 90% of TS patients in both 
clinic and community settings [70]. Figure 2 depicts the time course of common 
comorbidities in relation to tic symptoms, as experienced by patients with TS (Fig. 2). 
 
Fig. 2. Clinical course of Tourette syndrome and associated conditions. Figure depicts 
severity of premonitory urges, tics, or comorbid conditions symptoms associated with 
Tourette syndrome. Width bars correspond to severity of symptoms of each condition 







Roughly one-third to one-half of individuals with TS experience recurrent 
obsessive- compulsive (OC) symptoms [71-73]. Genetic, neurobiological, and treatment 
response studies suggest there may be qualitative differences between tic-related forms of 
OCD and cases of OCD not related to tics. Specifically, tic-related OCD has a male 
preponderance, an earlier age of onset, a poorer level of response to standard anti-
obsessional medications, and a greater likelihood of first-degree family members with a 
tic disorder [74]. Symptomatically the most common obsessive-compulsive symptoms 
encountered in TS patients are obsessions concerning a need for symmetry or exactness, 
repeating rituals, counting compulsions, and ordering/arranging compulsions [73]. Also, 
obsessive-compulsive symptoms, when present, in children with TS, appear more likely 
to persist into adulthood than the tics themselves [29]. OCD with comorbid tics is less 
responsive to SSRI pharmacotherapy and more responsive to antipsychotic augmentation 
than OCD in patients without tics [75, 76]. OCD patients with and without tic disorders 
appear equally responsive to cognitive-behavioral therapy [76]. 
Baseline data from a study of 158 youth with a chronic tic disorder (TD) showed 
children with comorbid OCD (53% of subjects) experienced more severe tics, increased 
levels of depressive and anxious symptoms, heightened psychosocial stress and poorer 
global functioning [77]. The authors concluded TD with OCD is a more severe subtype 
of TD and describes children with more internalizing disorders than those without OCD 
[77]. By contrast, another exploratory study involving 306 children with TD, OCD, or 
TD + OCD, failed to show that those with TD + OCD exhibited increases in tic severity 




Attention-Deficit Hyperactivity Disorder: 
 
Roughly 30–50% of children with TS are diagnosed with comorbid ADHD [72]. 
This rate of comorbid ADHD is higher in clinical samples. Although the etiological 
relationship between TS and ADHD is unclear, it is clear individuals with both TS and 
ADHD are at a much greater risk for a variety of poor outcomes including greater 
academic and social impairment [79-83]. Children with TS are often regarded as more 
aggressive, more withdrawn, and less popular than their classmates, and comorbidity with 
ADHD is associated with these difficulties [84]. Surprisingly, levels of tic severity are 
less predictive of peer acceptance than is the presence of ADHD [83]. Comorbid ADHD 
symptoms in children with tics are responsive to similar pharmacological treatment as are 
ADHD symptoms in children without tics [85]. Therefore, prompt screening of ADHD 
symptoms in children with tic disorders is imperative. We suggest examination of recent 
practice parameters for a thorough review of the diagnosis, assessment, and treatment of 
ADHD [86, 87]. 
Impulse Control Disorders: 
 
In addition to the high frequency of such comorbid conditions as ADHD and 
OCD, many children with TS have been noted to exhibit rage attacks, self-injurious 
behavior, inappropriate sexual activity, discipline problems, sleep disturbances, and other 
forms of impulse control disorders. Disruptive, Impulse-Control, and Conduct Disorders 
are currently listed as a category within the DSM-V [9]. “Impulsivity is defined as the 
failure to resist an impulse, drive, or temptation that is potentially harmful to oneself or 
others. It is evidenced behaviorally as carelessness; an underestimated sense of harm; 




toward risk-taking and pleasure- and sensation-seeking” [70]. Wright et al. review TS as 
it relates to impulse-control disorders, specifically, intermittent explosive disorder (IED), 
self-injurious behavior (SIB), and other forms of impulse-control disorder. 
This type of disinhibited behavior is inextricably linked to tics. For instance, some 
individuals will have the urge to make a loud vocal tic in a quiet library upon seeing the 
sign, “Quiet Please.” Similarly, one can feel the need to jerk his shoulder after someone 
lightly puts their hand on it. This type of behavior could represent the disrupted sensory 
gating in that the light stimulus is bothersome and can create a site of unpleasant urge. 
Furthermore, there is the example of a physicist during WWII, who had to relinquish his 
job in a high energy physics laboratory because whenever he saw the sign, “Danger High 
Voltage,” he had the strong urge to touch the apparatus. These types of tics are seen as 
reflexive tics to specific sensory clues, but often appear as disinhibited or impulsive 
behavior. 
It is estimated between 23% and 40% of clinically-referred TS subjects report 
distressing behavioral symptoms, such as sudden unpredictable anger, irritability, temper 
outbursts, and aggression [70]. A part of intermittent explosive disorder, rage attacks 
have been linked to TS since as early as 1998, when it was suggested individuals with TS 
and another comorbid condition, such as ADHD or OCD, are more likely to also 
experience rage attacks [88]. Since then, a study in 2008 showed that of 314 children in a 
Danish cohort of TS patients, 109 experienced rage attacks. Interestingly, when 
examining the presence of rage attacks within different subgroups, it was noted rage 
attacks were present in the greatest percentage (70.6%) of children who have TS with 




similar to the 50.9% of children with TS and OCD who experience rage. In those children 
who have TS alone, 36.7% exhibited rage attacks [89]. These data could support the 
suggestion that impulsivity and compulsivity are interlinked. Another hypothesis as to 
why OCD is linked to rage attacks in TS patients is that the sudden, impulsive outbursts 
of anger are a result of a disruption to routines that are linked to the compulsivity present 
in these patients [70]. In 2003, a questionnaire was developed in order to screen TS 
patients for episodic rage according to their symptoms. In this study, 48 children with TS, 
ages 7–17, were screened to explore rage attack phenomenology, and the investigators 
used a cluster analysis to identify four potential subgroups of TS with rage: specific urge 
resolution, environmentally secure reactivity, nonspecific urge resolution, or labile non-
resolving [90]. 
Furthermore, self-injurious behavior (SIB) has been consistently associated with a 
subgroup of TS patients. Of the 9 patients described by Gilles de la Tourette in 1885, 2 of 
them were described as exhibiting SIB. Self-injurious behavior has been reported in 
anywhere between 14.8% and 29% of TS subjects [91, 92]. Additionally, the proportion 
of SIB present in those with TS is higher in those with comorbid ADHD and who are 
older in age. In those patients with ADHD and TS, age of onset of SIB was 7.4 years, as 
compared to 10 years in those without ADHD [91]. Examples of types of SIB noted are 
biting one's tongue or lip, head-banging, body punching/slapping, head or face 
punching/slapping, body-to-hard-object banging, and poking sharp objects into one's 
body [70]. 
The co-occurrence of impulse-control disorders and TS has further implications 




gratification, the tendency toward making decisions based on immediate reward, they are 
distractible, and they are generally disinhibited, all of which can lead to behavior that 
does not comply with cultural norms. If impulsivity and compulsivity are thought to be 
opposite ends of a spectrum, TS would be considered a mixture of the two. While 
compulsions are driven by an attempt to reduce anxiety, impulsions are driven by an 
attempt to obtain arousal and gratification [70]. 
Concluding Thoughts: 
 
Tourette syndrome is a neuropsychiatric disorder characterized by multiple motor 
and vocal tics. In the majority of children with TS, tic symptoms diminish significantly 
during adolescence. Most individuals with TS experience associated sensory phenomena 
such as premonitory urges and somatic hypersensitivity that are often as distressing as the 
tics themselves. On the other hand, for many individuals with TS, the tics are neither the 
most prominent nor distressing part of the disorder. The majority of individuals with TS 
reaching clinical attention have common comorbid conditions such as ADHD, OCD and 
impulse control disorders. Proper diagnosis and treatment of TS involves appropriate 
evaluation and recognition, not only of tics, but also of these associated conditions.  
Section 2. Psychostimulants and tics: 
 
Psychostimulants are recommended as the first line pharmacologic treatment for 
children with ADHD [87]. Psychostimulants have demonstrated a larger effect size when 
compared to placebo, as compared to alternative pharmacological treatments for ADHD 
[85].  Randomized controlled trials have demonstrated that psychostimulants are more 




treatment [93].  When ADHD is present in children with tics, the symptoms of ADHD 
typically cause greater impairment in academic performance, social relationships, and 
neuropsychological performance, especially executive functioning, than the tics 
themselves [81-83, 94, 95].  Psychostimulants have been shown to be equally efficacious 
in treating ADHD symptoms in children with ADHD and comorbid tics as in children 
with ADHD alone [85]. 
Clinical practice currently restricts the use of psychostimulant medications in 
children with ADHD and comorbid tics.  The limited use of psychostimulants in patients 
with ADHD and comorbid tic symptoms is likely partially attributable to warnings placed 
on the medications by regulatory agencies.  The Food and Drug Administration (FDA) 
currently requires that psychostimulants list tics and/or a family history of a tic disorder 
as a contraindication (methylphenidate) or significant adverse reaction (methylphenidate 
and amphetamines) to their use [96, 97].  FDA labeling warns parents that 
psychostimulants “should not be taken by their child” (methylphenidate) and/or “may not 
be right for your child” (amphetamines) if they have tics [98, 99]. 
Amphetamine/Dextroamphetamine labeling also warns the public to “use with caution in 
patients with Tourette’s syndrome; stimulants may unmask tics” [100]. The FDA 
warnings resulted largely from a series of case reports and case series, which were 
published in the 1970s and 1980s [101-111]. A particularly influential case series of 15 
children who developed tics while on psychostimulants helped lead the FDA in 1983 to 
require listing contraindications and significant adverse reactions to psychostimulant 




Since then, however, multiple randomized controlled trials (RCTs) have 
demonstrated no effect of psychostimulants on tics [113-116].  In fact, an NIH- and 
Tourette Syndrome Association-funded trial examining treatment of ADHD in children 
with tics concluded “that prior concerns that MPH worsens tics and that the drug should 
be avoided in patients with tics may be unwarranted” [113].  Recent meta-analyses 
examining pharmacological treatment of children with tics and ADHD demonstrated that 
methylphenidate did not significantly worsen tic symptoms and was beneficial in treating 
ADHD symptoms in children with both conditions [85, 117]. 
   There is, however, strong biological rationale to suggest that psychostimulants 
might exacerbate tics. Methylphenidate and dextroamphetamine induce stereotypies in 
rats in a dose-dependent manner [118-120]. Stimulant-induced stereotypies in rodents are 
hypothesized to be an animal model for tic disorders [121].  Furthermore, 
psychostimulants have been demonstrated to increase dopamine in the synaptic cleft 
[122] whereas the most effective anti-tic medications available, antipsychotic 
medications, act as dopamine antagonists [28, 123, 124]. 
   On the other hand, the timing of onset of ADHD and Tourette syndrome 
represents a possible confounder. Roughly 20% of children with ADHD go on to develop 
a chronic tic disorder [125]. When ADHD and tics co-occur in an individual, the onset of 
ADHD typically precedes that of tic symptoms by 2 to 3 years [28].  Therefore, it is 
difficult to determine whether the tics are a result of a side-effect of psychostimulants or 
if they were to occur anyway, as children with ADHD are at higher risk of developing 




wane in severity, so it is unclear whether a patient’s tics are going to naturally increase at 
a given time or if the increase is a result of psychostimulant side-effects. 
Clinicians are uncertain regarding use of psychostimulants in children with 
existing tics or a family history of tics because of conflict between strong FDA labeling 
contradicting psychostimulant use in this population and randomized, controlled trial and 
meta-analysis data suggesting efficacy without any apparent risk in the same population. 
Statement of Purpose and Hypothesis 
 
The goal of this meta-analysis is to provide an evidence base for future guidelines, 
warnings, and clinical decisions for the use of psychostimulants in children who develop 
tics after psychostimulant use or are judged to be at increased risk of developing tics prior 
to psychostimulant use.  We will examine all available data on side-effects in previous 
randomized, placebo-controlled trials of psychostimulants in childhood ADHD to 
determine the risk of new-onset or worsening of tics associated with psychostimulants 
compared to placebo.  We will conduct secondary analyses to examine the effects of 
psychostimulant type (methylphenidate vs. mixed amphetamine salt derivatives, long 
versus short-acting formulations), dose, duration, recorder of side-effects, trial design, 
and participant age on the risk of tics with psychostimulant treatment.  
Methods 
 
Search Strategy for Identification of Studies: 
 
Two reviewers (JMM and EFO) searched the electronic database of PubMed on 
August 18, 2013 for relevant studies using the search: (Attention deficit disorder with 




deficit*” OR “brain dysfunction”) AND (methylphenidate OR Ritalin OR Metadate OR 
Equasym OR Daytrana OR Concerta OR Dextroamphetamine OR amphetamine OR 
Adderall OR Vyvanse OR Dexedrine OR Dextrostat).  The search only utilized 
randomized controlled trials. The references of appropriate papers on the safety and 
efficacy of psychostimulant medications were also searched (by SCC) for citations of 
further relevant published and unpublished research.   
Selection of Studies: 
 
The titles and abstracts of studies obtained by this search strategy were examined 
by two reviewers (JMM and EFO) to determine inclusion in this meta-analysis. Any 
discrepancies were resolved by a final reviewer (MHB). Authors (SCC, CGC, and JMM) 
re-checked this work to make sure the database created was accurate. Eligibility for the 
study was based upon analysis of the full articles for the following criteria (1) they are 
randomized, double-blind, placebo-controlled clinical trials of psychostimulant 
medications (methylphenidate or dextroamphetamine derivatives) compared with placebo 
and (2) participants included are children and adolescents less than 18 years of age 
diagnosed with ADHD or hyperkinetic disorder by explicit criteria i.e. DSM or ICD 
criteria. Exclusion criteria for the studies included if (1) the study was not published in 
English, (2) the study population included only patients with ADHD plus another primary 
comorbidity i.e. mental retardation, pervasive developmental disorder, oppositional 
defiant disorder, tics, or anxiety, (3) the medication of interest was given for less than 7 
days in duration, (4) there were fewer than 10 subjects (crossover design) or fewer than 
20 subjects (parallel design), and (5) the primary goal of the trial was not treatment for 




neuropsychological measures were excluded).  We required medication/placebo each to 
be given for at least 7 days in trial because the authors a priori decided that this was the 
minimum required time needed in order to be confident regarding a change in tic 
symptoms.  A 7-day assessment period is similar to that utilized for common clinical 
rating scales of tic symptoms such as the Yale Global Tic Severity Scale [13].  We 
additionally restricted trials to treatment trials as studies utilizing non-treatment related 
outcome measures such as MRI, EEG or neuropsychological testing were less likely to 
systematically assess side-effects of medications. 
Meta-Analytic Procedures: 
 
Data was extracted by independent reviewers (SCC, JMM, CGC, and ZDS) on 
specially designed Microsoft Excel spreadsheets. Our primary outcome measure was the 
proportion of children reporting tics as a side-effect of medication.  When possible, 
clinician-rated side-effect measures were utilized as the main outcome measure.  When 
this information was unavailable, participant-rated, parent-rated, or teacher-rated side-
effect measures were used.  Reviewers additionally gathered data on trial medication, trial 
design, maximum daily medication dose, number of participants, mean age of 
participants, duration of active treatment in trials, who recorded side-effect ratings, and 
other relevant attributes and results of the studies.  Any disagreement among reviewers 
was mitigated through discussion and the procurement of more information from the 
study investigators when possible.  When agreement could not be attained between the 
initial reviewers, the senior investigator (MHB) resolved all disputes.  When information 
about proportion of tics was not available in the original manuscripts, the corresponding 




corresponding author was ineffective, pharmaceutical company databases were searched 
(by CGC) for the data.  
All statistical analyses were completed (by MHB) in Comprehensive Meta-
Analysis Version 2.   For our outcome measures of interest, proportion of subjects 
experiencing tics was analyzed using pooled risk ratio (RR).  Absolute risk difference 
(ARD) and number needed to harm (NNH) were also reported for the primary outcome as 
both the absolute and relative risks are clinically relevant when considering the use of 
medications. For all outcome measures, 95% confidence intervals (CIs) were conveyed. A 
fixed-effects model for meta-analysis was used, as well as a random-effects model in 
sensitivity analysis. Publication bias was assessed by plotting the effect size against 
standard error for each included trial (i.e., funnel plot). In addition, publication bias was 
statistically tested by the Egger’s test and by determining the association between sample 
size and effect size in meta-regression. We additionally reported the risk of new-onset or 
worsening of tics in both the psychostimulant and placebo groups in order to assist 
clinicians in decision-making.  We report results of a random effects model for these data 
as it is clear there was significant heterogeneity in how tics were assessed and the 
frequency that tics were reported within the placebo and psychostimulant groups based on 
trial methodology. 
For secondary analyses several subgroup analyses and meta-regressions were 
accomplished. Stratified subgroup analyses were conducted based on (1) type of 
psychostimulant (methylphenidate vs. mixed-amphetamine derivatives), (2) duration of 
action of medications (long-acting vs. short-acting psychostimulants), (3) recorder of 




test for subgroup differences (between group heterogeneity chi-square) in the mixed-
effects model of CMA to test for subgroup differences.  Meta-regression analysis was 
used to examine the effect of (1) maximum daily dose of psychostimulants utilized in 
trials, (2) length of active psychostimulant treatment, and (3) age of participants on the 
risk of developing new-onset or worsening of tics with psychostimulants compared to 
placebo.  All daily doses of psychostimulants were converted into methylphenidate 
equivalents using previously described methodology [126].  Our threshold for statistical 
significance was p<0.05 for the primary analysis, as well as for all stratified subgroup 





Fig. 3 depicts the selection of trials for this meta-analysis.  A total of 815 
references were identified in PubMED.  A total of 92 trials were eligible for inclusion.  Of 
these 92 trials, 16 trials published data on tics as a side-effect of psychostimulant 
medication. Authors of 6 additional trials responded to email requests with unpublished 
data regarding the risks of tics in psychostimulant trials. Therefore, a total of 22 trials, 
involving 2385 participants, were included in our meta-analysis [127-148].  The 





Fig. 3. Selection of studies. Note: ADHD = attention-deficit/hyperactivity disorder 
 
Table 7. Characteristics of Included Trials in the Meta-Analysis of the Risk of Tics with 
Psychostimulants.  














1974 MPH IR MPH Short 0.5 - 1 
mg/kg/day 
Crossover 4 week 37 8.9  
Gittelman-
Klein et al. 
[128] 




1980 MPH IR MPH Short 0.4 
mg/kg/day 
Crossover 3-4 weeks 30 8.4  
Rapport et 
al. [130] 
1985 MPH IR MPH Short 15 mg/day Crossover 1 week 12 6-10  
Barkley et 
al. [131] 
1990 MPH IR MPH Short 0.5 mg/kg 
BID 
Crossover 7-10 days 82  8.2  
Buitelaar et 
al. [132] 
1996 MPH IR MPH Short 10 mg 
BID 
Parallel 4 weeks 21  9.2  
Stein et al. 
[133] 
1996 MPH IR MPH Short 20 mg TID  Crossover 1 week  25 8.0  
Gillberg et 
al. [134] 
1997 MAS IR AMP Short 45 mg/day  Parallel 3 months 56 9  
Firestone 
et al. [135] 
1998 MPH IR MPH Short 0.5 mg/kg 
BID 
Crossover 7-10 days 
 
32 4.8  
Pliszka et 
al. [136] 
2000 MPH IR MPH Short 50 mg/day  Parallel 3 weeks 58 8.1  





MPH Long 54 mg/day Crossover 1 week 68 9.1  





et al. [138] 
2001 OROS® 
MPH 
MPH Long 54 mg/day Parallel 4 weeks 282 9.0  
MPH IR  MPH Short 15 mg TID 
Greenhill 
et al. [139] 
2002 MPH MR MPH Long 60 mg/day  Parallel 3 weeks 316  9  
McCracken 
et al. [140] 
2003 MAS XR AMP Long 30 mg/day Crossover 1 week 49  9.5  
MAS IR AMP Short 10 mg/day 




MPH Long 54 mg/day Crossover 1 week 47 9  
Findling et 
al. [142] 
2006 EqXL MPH Long 60 mg/day  Parallel 3 weeks 318  9.5  




2006 MPH IR MPH Short 1 mg/kg 
divided 
daily 




2008 MPH Patch MPH Short 30 mg 
9hr/day 
Parallel 2 weeks 274  8.7  
OROS® 
MPH  





MPH Long 54 mg/day Parallel 6 weeks 293  10.2  
Silva et al. 
[146] 
2008 dMPH ER MPH Long 30 mg/day Crossover 1 week 82 9.4  
MPH MR MPH Long 54 mg/day 
Solanto et 
al. [147] 
2009 MPH IR MPH Short 50 mg/day Crossover 1 week 25 8.8  
Lee et al. 
[148] 
2011 MPH IR MPH Short 0.5 
mg/kg/day 
Crossover 1 week 157 9.0  
Note: AMP = amphetamine; BID = twice daily; dMPH = dexmethylphenidate; EqXL = 
Equasym XL; IR = immediate release; MAS = mixed amphetamine salts; MPH = 
methylphenidate; MR = modified-release; MTS = methylphenidate transdermal system; 
OROS = trademarked acronym denoting Osmotic Controlled-Release Oral Delivery 
System; Ref = reference; TID = 3 times daily; XR/ER = extended-release. 
 
Risk of new-onset or worsening of tics with psychostimulants: 
 
Meta-analysis of 22 studies involving 2385 participants demonstrated no 
significant increase in the risk of new-onset or worsening of tics when comparing 
psychostimulant to placebo (Fig. 4), RR=0.99 (95% CI: 0.78 to 1.27), z=-0.05, p=0.96.   
There was no significant heterogeneity between trials (I2 =12.7%, p=0.28) or evidence of 
publication bias (Egger’s test: p=0.88).  A random effects model produced similar 
estimates of risk when examined in a sensitivity analysis (RR=0.97 (95%CI: 0.72 to 





Fig. 4. Relative risk of tics with psychostimulants compared to placebo. Note: Forest plot 
comparing the relative risk of tics in participants treated with psychostimulants compared 
to placebo in short-term, randomized-controlled trials. Meta-analysis demonstrated no 
significant difference in the risk of tics with stimulants compared to placebo (risk ratio = 
0.99, 95% confidence interval = 0.78 to 1.27, z = -0.05, p = 0.96). 
 
There was also no evidence of increased risk of new-onset or worsening of tics 
when examining absolute risk difference of tics with psychostimulants compared to 
placebo (Fig. 5), ARD=0.001 (95% CI: -0.009 to 0.011), z=0.18, p=0.86).  There was no 
significant heterogeneity among trials (I2 = 9.6%, p=0.32) or evidence of publication bias 
(egger’s test: p=0.88).  A random effects model produced similar estimates of risk when 






Fig. 5. Absolute risk difference of tics between psychostimulants and placebo. Note: 
Forest plot depicting the absolute risk difference of tics in participants treated with 
psychostimulants compared to placebo in short-term, randomized-controlled trials. 
Meta-analysis demonstrated no significant difference in the risk of tics with stimulants 
compared to placebo (absolute risk difference = 0.001, 95% confidence interval = -0.009 
to 0.011, z = 0.18, p = 0.86). 
 
In random effects meta-analysis, 5.7% of children in the psychostimulant arms of 
trials reported new onset or worsening of tics (event rate=5.7% (95% CI: 3.7% to 8.6%), 
I2 = 72%, p<0.001).  However, the event rate for new-onset or worsening of tics was 
higher in the placebo arms of included trials (event rate=6.5% (95% CI: 4.4% to 9.5%), 
I2 = 64%, p<0.001). 





Stratified subgroup analysis demonstrated no significant difference in risk of new-
onset or worsening of tics (test for subgroup differences χ2=0.26, p=0.61) between 
methylphenidate derivatives (RR=1.02 (95% CI: 0.78 to 1.33), k=20, z=0.14, p=0.89) and 
amphetamine derivatives (RR=0.84 (95% CI: 0.42 to 1.68), k=4, z=-0.49, p=0.63). 
Long- vs. Short-acting psychostimulants: 
  
Stratified subgroup analysis demonstrated no significant difference in risk of new-
onset or worsening of tics (test for subgroup differences χ2=0.22, p=0.64) between short-
acting (RR=1.04 (95% CI:  0.76 to 1.43), z=0.25, p=0.80) and long-acting 
psychostimulants (RR=0.92 (95% CI: 0.62 to 1.38), z=-0.40, p=0.69).  
Psychostimulant Dose:  
 
Meta-regression demonstrated no significant association between dosage of 
psychostimulants and the risk of new-onset or worsening of tics (β=-0.0023 (95% CI:       
-0.0142 to 0.0097), z=-0.37, p=0.71).  There was no significant association between 
dosage of psychostimulants and risk of new-onset or worsening of tics when analysis was 
restricted to methylphenidate (β=-0.0005 (95% CI:  -0.0159 to 0.0150), z=-0.06, p=0.95) 
or amphetamine derivatives (β=-0.0028 (95% CI:  -0.0280 to 0.0224), z=-0.22, p=0.83). 
Duration of Active Treatment: 
  Meta-regression demonstrated no significant association between duration of 
active treatment and the risk of new-onset or worsening of tics associated with 
psychostimulant medication (β=-0.010 (95% CI:  -0.022 to 0.002), z=-1.69, p=0.09).  





Stratified subgroup analysis demonstrated no significant difference in risk of new-
onset or worsening of tics based on whether clinicians or non-clinical informants (parents 
and/or teachers) were rating tic outcomes (test for subgroup differences χ2=1.49, p=0.22).  
The relative risk of tics was non-significantly lower when utilizing clinician recorders of 
tics (RR=0.72 (95% CI:  0.41 to 1.29), z=-1.10, p=0.28) rather than non-clinical report 
(RR=1.08 (95% CI:  0.82 to 1.42), z=0.53, p=0.59).   
Trial Design: 
 
Crossover studies reported a significantly greater association of new-onset or 
worsening of tics with psychostimulants compared to parallel-group studies (test for 
subgroup differences χ2=5.3, p=0.02).  However, neither crossover trials (RR=1.23 (95% 
CI: 0.90 to 1.68), z=1.3, p=0.19) nor parallel-group studies (RR=0.67 (95% CI: 0.44 to 
1.02), z=-1.88, p=0.06) reported a significant association of tics with psychostimulant 
use.   
Age of Participants: 
 
Meta-regression demonstrated no significant association between participants’ age 
and measured risk of new-onset or worsening of tics with psychostimulant medications 
(β=-0.39 (95% CI: -0.83 to 0.05), z=-1.75, p=0.08).  
Discussion 
 
Meta-analysis demonstrated no statistically significant relationship between 
psychostimulant use and new-onset or worsening of tics in children with ADHD. 
Specifically, the relative risk of new-onset or worsening of tics was 0.99 (95% CI: 0.78 to 




Furthermore, we found no association between risk of new-onset or worsening of tics and 
dosage, type or duration of use, psychostimulant agent, or recorder of side-effect data. 
Taken together, data from this meta-analysis is most consistent with an absence of a risk 
of new-onset or worsening of tics with psychostimulant medications.  However, the 
power of this meta-analysis is not sufficient to rule out the possibility of a small increased 
risk of tics with psychostimulant use.  However, based on the available data, it remains 
equally likely that psychostimulants reduce the risk of tics as they do raise the risk of tics.   
Current evidence from this meta-analysis and previous work examining the effects 
of psychostimulants in children with tics and ADHD does not support the clinical practice 
of restricting the use of psychostimulants in children with tics or at high risk of 
developing tics [98, 99].  Previous meta-analysis examining the effects of 
methylphenidate in children with ADHD and comorbid tics demonstrated that 
psychostimulants appear to have a similar effect size in reducing ADHD symptoms in 
children with comorbid tics as in children without comorbid tic disorders [85].  
Furthermore, there was no evidence that psychostimulants worsened tic symptoms in 
children with both ADHD and tics [85].   Randomized controlled trials in children with 
ADHD and tics have further demonstrated that combination treatment with 
methylphenidate and clonidine is more effective than either medication alone [113].  Our 
meta-analysis extends upon these previous results by demonstrating that there is no 
increased risk of new-onset or worsening tics with psychostimulant use compared to 
placebo in meta-analysis of randomized, placebo-controlled trials in children with ADHD 




The results of this meta-analysis also provide strong support for re-challenging 
children (or even continuing children on psychostimulants) who develop tics that are 
temporally related to the initiation of psychostimulants. Assuming the absolute risk 
difference of 0.001 observed in the meta-analysis, the number needed to harm for new-
onset or worsening tics with psychostimulants is 1000 (95% CI: 77 to ∞).  If additionally 
assuming the baseline risk of experiencing new-onset tics over short-term trials of 
medications is equivalent to the 6.5% observed in the placebo arms of randomized, 
controlled trials of psychostimulants then in a child who develops tics shortly after 
initiating psychostimulants, the tics are 65-fold more likely to be the result of coincidence 
than caused by the medication.  Even assuming the highest risk of tics ( 0.011 -- at the 
upper bound of the 95% confidence interval of absolute risk difference), when new-onset 
or worsening of tics appear after the initiation of psychostimulants, the tics are 6-fold 
more likely to be a result of coincidence than be caused by the medications.  Given the 
absence of data suggesting psychostimulants make existing tics worse [85, 113], re-
challenging appears reasonable, whether or not the tics persist after discontinuation of the 
psychostimulant. Re-challenging appears particularly advisable in children whose ADHD 
does not respond sufficiently to other medications such as alpha-2 agonists and 
atomoxetine, which are used to help ADHD and may additionally help improve tics 
symptoms [124, 149, 150]. 
  There are several limitations to this meta-analysis that may have affected its 
findings. Foremost among these limitations is the fact that a limited number of 
randomized, placebo-controlled trials of psychostimulants for children with ADHD 




side-effect data, if it existed, could lead to publication bias that would likely exaggerate 
the association between tics and psychostimulants. Many trials only report side-effects 
that were above a certain percent threshold in the active treatment group or were 
statistically different between groups.  This practice would also lead to an inflated 
estimate of the association between psychostimulants and tics, as trials with increased 
associations would be selectively published and included in our meta-analysis.  In order 
to minimize this potential bias, we emailed authors of potentially eligible trials that did 
not include data on tics in order to obtain additional data to include in the meta-analysis.  
However, many authors were unresponsive or did not have available data from the trial, 
so this potential bias should not be discounted.   Another potential limitation is the 
inclusion of crossover trials in addition to parallel group trials in this meta-analysis.  We 
made the decision to include crossover trials to maximize power in our meta-analysis.  
Crossover trials of psychostimulants were designed using washout periods of sufficient 
time to eliminate any beneficial effects of psychostimulants before the start of the next 
phase of the trial.  It remains quite possible that if tics occurred as an adverse event in 
crossover trials, they might still carryover to the next trial phase and thus dampen our 
ability to detect tics as an adverse effect of treatment.  However, stratified analysis 
demonstrated an increased measured risk of tics with psychostimulants in crossover 
studies compared to parallel-group studies, arguing against this phenomenon occurring.  
An additional potential limitation is the heterogeneity in how tics were assessed as a side-
effect between trials – some trials relied on parent-report, whereas others included direct 
observation of subjects.   We conducted stratified subgroup analysis based on whether or 




who was rating side-effect symptoms.  Additionally, some trials require significant 
impairment for side-effects to be reported while others do not.   Because of the manner in 
which tics are reported as a side-effect in trials, we are unable to determine whether 
individual reported adverse events in trials were due to (1) a new-onset of tics or (2) 
worsening of pre-existing tics.  We therefore are only able to comment on the aggregate 
risk of either of these two events occurring but not of each event individually.  It should 
also be emphasized that our data only applies to use of psychostimulants within the 
recommended therapeutic dose range.  Both data in animal models and children with tics 
has suggested that supratherapeutic doses of psychostimulant medications may worsen 
tics [114, 118-120]. Another limitation to this meta-analysis is the fact that the studies 
included in our meta-analysis do not have available data on whether tics resolve or persist 
after medication or placebo discontinuation. 
Conclusion 
 
In conclusion, this meta-analysis suggests that new-onset or worsening of tics 
appear to occur at a fairly high rate (5-7%) in the period immediately after starting 
psychostimulants.  However, tics were no more likely to be associated with 
psychostimulant treatment than with placebo. When tics occur in temporal relationship to 
psychostimulant use, this relationship is much more often coincidental than causative.  
There are several potential confounding factors that may explain the high-rate of tics 
reported in children after starting psychostimulants.  The high rate of tics observed in 
children with ADHD and the waxing-and-waning nature of tic symptoms may explain 
some of this phenomenon [151].  Additionally, tics have been demonstrated to worsen 




often coincides with the start of the academic year or in the face of increasing 
academic/social difficulties – natural periods of high stress, excitement and fatigue for 
children.  Therefore, the temporal relationship between psychostimulant use and new-
onset tics could be largely or completely attributable to confounding. Future research 
investigating side-effects associated with medications could be greatly enhanced by 
requiring pivotal trials to make side-effect data publically available. Additionally, this 
research would benefit from a standardized method of reporting and measuring tics and 
other side-effects in clinical trials of psychostimulants. 
In summary, new-onset or worsening tics are commonly experienced by children 
with ADHD in both the active and placebo groups of psychostimulant trials. There is no 
evidence of an association between psychostimulant use and risk of new-onset or 
worsening tics in placebo-controlled trials. When new-onset or worsening of tics occurs 
after the initiation of a psychostimulant medication, it is much more likely to be a result 
of coincidence than caused by the medication. Using psychostimulant medications in 
children with ADHD and comorbid tics (or with a family history of tics) should be 
considered, especially when agents that target both ADHD and tic symptoms (e.g. alpha-2 
agonists) have failed. Re-challenging children who experience new-onset or worsening 
tics on psychostimulants appears to be a reasonable treatment strategy if ADHD 
symptoms remain impairing. 
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